Basilea Pharmaceutica AG (SWX:BSLN)

Switzerland · Delayed Price · Currency is CHF

52.00

-0.50 (-0.95%)

Mar 6, 2026, 10:52 AM CET

10.64% (1Y)

Market Cap	645.31M
Revenue (ttm)	232.38M
Net Income (ttm)	40.24M
Shares Out	12.29M
EPS (ttm)	3.14
PE Ratio	16.71
Forward PE	13.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,313
Average Volume	39,512
Open	52.50
Previous Close	52.50
Day's Range	51.10 - 52.50
52-Week Range	37.50 - 59.70
Beta	0.45
RSI	46.81
Earnings Date	Feb 17, 2026

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a cli... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 189

Stock Exchange SIX Swiss Exchange

Ticker Symbol BSLN

Full Company Profile

Financial Performance

In 2025, Basilea Pharmaceutica AG's revenue was 232.38 million, an increase of 11.43% compared to the previous year's 208.54 million. Earnings were 40.24 million, a decrease of -48.14%.

Financial Statements

News

Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...

9 days ago - GlobeNewsWire

Basilea Pharmaceutica AG (BPMUF) Q4 2025 Earnings Call Transcript

16 days ago - Seeking Alpha

Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance

15% royalty income increase 11% total revenue increase Tripled net cash position Phase 3 program with fosmanogepix progressing as planned Financial guidance FY 2026: Double-digit increase in total rev...

17 days ago - GlobeNewsWire

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacteria...

25 days ago - GlobeNewsWire

Basilea provides portfolio update and outlook

Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam Fosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal infect...

2 months ago - GlobeNewsWire

Prokaryotics and Basilea enter collaboration to develop a novel broad-spectrum antifungal for severe invasive infections

UNION, N.J., Jan. 7, 2026 /PRNewswire/ -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infectives, today announced an agreement ...

2 months ago - PRNewsWire

Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic

Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacteria...

3 months ago - GlobeNewsWire

Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI

BOSTON--(BUSINESS WIRE)--Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage biopha...

3 months ago - Business Wire

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 04, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...

4 months ago - GlobeNewsWire

Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam

- Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million

5 months ago - GlobeNewsWire

Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meetin...

6 months ago - GlobeNewsWire

Basilea Pharmaceutica AG (BPMUF) Q2 2025 Earnings Conference Call Transcript

Basilea Pharmaceutica AG (OTC:BPMUF) Q2 2025 Earnings Conference Call August 19, 2025 10:00 AM ET Company Participants Adesh Kaul - Chief Financial Officer David Veitch - Chief Executive Officer Marc ...

7 months ago - Seeking Alpha

Basilea on track with strong 2025 half-year results

Cresemba ® and Zevtera ® -related revenues rise by 24% to CHF 90.5 million Total revenue grows significantly by 36% to CHF 104.0 million Operating profit surges by 160% to CHF 24.0 million Operating c...

7 months ago - GlobeNewsWire

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting t...

7 months ago - GlobeNewsWire

Assessment of the 14-Alpha Demethylase Inhibitors Pipeline Landscape 2025, Featuring Insights Into Oteseconazole (Mycovia Pharmaceuticals) and Isavuconazonium (Basilea Pharmaceutica)

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "14-alpha Demethylase Inhibitors - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides compre...

10 months ago - GlobeNewsWire

Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea

Allschwil, Switzerland, April 24, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial a...

11 months ago - GlobeNewsWire

Basilea Pharmaceutica AG (BPMUF) Q4 2024 Earnings Call Transcript

Basilea Pharmaceutica AG (OTC:BPMUF) Q4 2024 Earnings Conference Call February 18, 2025 10:00 AM ET Company Participants David Veitch - Chief Executive Officer Adesh Kaul - Chief Financial Officer Mar...

1 year ago - Seeking Alpha

Basilea Pharmaceutica AG (BPMUF) Q2 2024 Earnings Call Transcript

Basilea Pharmaceutica AG (OTC:BPMUF) Q2 2024 Results Conference Call August 13, 2024 10:00 AM ET Company Participants David Veitch - Chief Executive Officer Adesh Kaul - Chief Financial Officer Marc E...

1 year ago - Seeking Alpha

US FDA approves Basilea Pharmaceutica's antibiotic

The U.S. health regulator approved Basilea Pharmaceutica's antibiotic for bacterial infections including multidrug-resistant strains, the FDA said on Wednesday.

2 years ago - Reuters

Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio

Increased Cresemba ® and Zevtera ® -related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidance Operating profit of CHF 19.2 million and net profit of CHF 10.5 million, signifi...

2 years ago - GlobeNewsWire